4-Methoxy-2-(trifluoromethyl)phenacyl bromide | 541549-99-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-Methoxy-2-(trifluoromethyl)phenacyl bromide
• 英文别名: 2-bromo-1-[4-methoxy-2-(trifluoromethyl)phenyl]ethanone
• CAS: 541549-99-9
• 化学式: C₁₀H₈BrF₃O₂
• 分子量: 297.072
• InChiKey: XVWBDQQJCINZNX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  4-甲氧基-2-三氟甲基苯甲酸 在 草酰氯 作用下， 以 正己烷 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 3.0h， 生成 4-Methoxy-2-(trifluoromethyl)phenacyl bromide
  参考文献：
  名称：

  IMIDAZOLE AND TRIAZOLE COMPOUNDS AS DGAT-1 INHIBITORS

  摘要：

  公开号：

  EP2862856B1

文献信息

• BENZOIC ACID DERIVATIVES
  申请人：Gillespie Paul

  公开号：US20130079346A1

  公开（公告）日：2013-03-28

  There are disclosed are compounds of the formula: wherein R1 and R2 are as disclosed herein, which are eIF4E inhibitors useful in the treatment of cancers. Also disclosed are compositions comprising the compounds, as well as methods of treating cancer using the compounds.

  已披露的化合物的公式如下：其中R1和R2如本文所述，它们是eIF4E抑制剂，可用于治疗癌症。还披露了包含这些化合物的组合物，以及使用这些化合物治疗癌症的方法。
• AROMATIC HETEROCYCLIC COMPOUND
  申请人：Mitsubishi Tanabe Pharma Corporation

  公开号：EP2862856A1

  公开（公告）日：2015-04-22

  The compound represented by the general formula: wherein ring A is benzene which may be substituted and the like; ring B is benzene which may be substituted and the like; X is a single bond and the like; Y is alkyl which may be substituted and the like; Z is CR1 or nitrogen atom; R1 is hydrogen and the like; R2 is alkyl which may be substituted and the like or a pharmaceutically acceptable salt thereof is useful as a prevention/treatment agent of obesity, diabetes, and the like.

  由通式表示的化合物：其中环 A 是苯，可被取代等；环 B 是苯，可被取代等；X 是单键等；Y 是烷基，可被取代等；Z 是 CR1 或氮原子；R1 是氢等；R2 是烷基，可被取代等或其药学上可接受的盐，可用作肥胖症、糖尿病等的预防/治疗剂。
• Aromatic heterocyclic compound
  申请人：MITSUBISHI TANABE PHARMA CORPORATION

  公开号：US10308636B2

  公开（公告）日：2019-06-04

  The compound represented by the general formula: wherein ring A is benzene which may be substituted and the like; ring B is benzene which may be substituted and the like; X is a single bond and the like; Y is alkyl which may be substituted and the like; Z is CR1 or nitrogen atom; R1 is hydrogen and the like; R2 is alkyl which may be substituted and the like or a pharmaceutically acceptable salt thereof is useful as a prevention/treatment agent of obesity, diabetes, and the like.

  由通式表示的化合物：其中环 A 是苯，可被取代等；环 B 是苯，可被取代等；X 是单键等；Y 是烷基，可被取代等；Z 是 CR1 或氮原子；R1 是氢等；R2 是烷基，可被取代等或其药学上可接受的盐，可用作肥胖症、糖尿病等的预防/治疗剂。
• Process for producing (R)-styrene oxides
  申请人：SUMIKA FINE CHEMICAL COMPANY, LTD.

  公开号：EP0735142B1

  公开（公告）日：2001-10-24
• BENZOIC ACID DERIVATIVES AS EIF4E INHIBITORS
  申请人：F.Hoffmann-La Roche AG

  公开号：EP2758380A1

  公开（公告）日：2014-07-30